MindBio prepares for Phase 2 clinical trials after receiving one million microdoses of LSD

Written By Tim Wade

MindBio ‘s CEO Justin Hanka recently visited the company’s Canadian manufacturer, which is fully licensed by the Canadian Government to manufacture GMP grade LSD for the pharmaceutical industry. This LSD will be used to create a novel sub-lingual formulation for LSD microdosing.

Following a secure chain of custody, MindBio announced that its initial delivery of 1,000,000 microdoses of LSD has arrived at its labs for process in preparation for two separate, fully-funded, Phase 2 take-home LSD microdosing clinical trials.

Tim Wade
Previous

MindBio LSD microdosing research reveals significant positive impact on sleep quality
Next

MindBio publish peer reviewed paper in Biological Psychiatry journal